Friedreich's ataxia
| Friedreich's ataxia | |
|---|---|
| Synonyms | Spinocerebellar ataxia, FRDA, FA |
| Pronounce | |
| Field | Neurology |
| Symptoms | Lack of coordination, balance issues, gait abnormality |
| Complications | Cardiomyopathy, scoliosis, diabetes mellitus |
| Onset | 5–15 years |
| Duration | Long-term |
| Types | |
| Causes | Genetic |
| Risks | |
| Diagnosis | Medical history and physical examination |
| Differential diagnosis | |
| Prevention | |
| Treatment | Physical therapy |
| Medication | |
| Prognosis | Shortened life expectancy |
| Frequency | 1 in 50,000 (United States) |
| Deaths | |


Friedreich's ataxia (FRDA or FA) is an autosomal recessive genetic disorder characterized by progressive damage to the nervous system. It manifests in difficulty with walking, loss of sensation in the arms and legs, and impaired speech (Dysarthria), with symptoms typically emerging between the ages of 5 and 15. The condition often necessitates the use of mobility aids such as canes, walkers, or wheelchairs in teenage years due to increasing mobility challenges.
Genetics[edit]
FRDA is caused by mutations in the FXN gene, which leads to reduced production of frataxin, a protein essential for cellular energy production and iron regulation in the mitochondria. The autosomal recessive pattern of inheritance means that an individual must inherit two copies of the mutated gene, one from each parent, to develop the condition.
Symptoms and Progression[edit]
The hallmark symptom of FRDA is ataxia, or coordination and balance problems, due to the degeneration of nerve tissue in the spinal cord and nerves that control muscle movement in the arms and legs. Initial signs often include difficulty in walking, changes in speech, and a loss of reflexes. As the disease progresses, individuals may develop hypertrophic cardiomyopathy (a form of heart disease), scoliosis (curvature of the spine), and diabetes mellitus.
Sensory loss in the extremities worsens over time, leading to a decreased ability to feel vibrations and touch. Vision and hearing loss can also occur as the disease advances.
Diagnosis[edit]
Diagnosis of FRDA is primarily based on clinical assessment, family history, and genetic testing to identify mutations in the FXN gene. Additional tests, including echocardiograms, electrocardiograms, and glucose tolerance tests, may be conducted to detect associated conditions such as cardiomyopathy and diabetes.
Treatment and Management[edit]
There is no cure for Friedreich's ataxia, but treatment focuses on managing symptoms and improving quality of life. This may include the use of mobility aids, physical therapy to maintain muscle strength and coordination, and medications to manage heart problems and diabetes. Surgical interventions for scoliosis and other complications may be necessary in some cases.
Speech therapy and assistive devices can help manage communication difficulties, while regular monitoring and treatment of heart disease and diabetes are crucial for maintaining health.
Prognosis[edit]
The progression of FRDA varies between individuals. Most people with the condition become wheelchair-bound within 15 to 20 years after the onset of symptoms. Life expectancy can be reduced, primarily due to heart disease, but many individuals with FRDA live into their 60s or beyond with proper medical care.
Research[edit]
Ongoing research aims to find effective treatments and a potential cure for FRDA. Efforts include gene therapy, antioxidants, and medications designed to increase frataxin production or improve mitochondrial function.
See Also[edit]
| Diseases of the nervous system, primarily CNS (G04–G47, 323–349) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| Mitochondrial diseases | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
see also mitochondrial proteins
|
| Non-Mendelian inheritance: anticipation | ||||||
|---|---|---|---|---|---|---|
|
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian


